Welcome to our dedicated page for Sotera Health Company news (Ticker: SHC), a resource for investors and traders seeking the latest updates and insights on Sotera Health Company stock.
Sotera Health Company (Nasdaq: SHC) is a leading global provider of sterilization, lab testing, and advisory services, primarily serving the medical device, pharmaceutical, and food industries. The company operates through three main segments: Sterigenics, Nordion, and Nelson Labs. Sterigenics offers terminal sterilization and irradiation services, including gamma and electron beam irradiation, and EO processing. Nordion supplies Co-60 and gamma irradiators, which are critical for the gamma sterilization process. Nelson Labs specializes in outsourced microbiological and analytical chemistry testing.
The company is known for its commitment to ensuring the safety and quality of healthcare products through its comprehensive suite of services. Sotera Health’s lab services cover analytical chemistry, medical device testing, pharmaceutical lab testing, and microbiology testing, helping clients identify and mitigate risks. The advisory segment supports clients in navigating regulatory requirements throughout the product lifecycle.
Recently, Sotera Health has achieved significant milestones, including a 6.7% increase in net revenues for its Sterigenics segment in Q3 2023, driven by favorable pricing and currency exchange rates. Nordion reported a 14.3% increase in net revenues, reflecting robust demand for its services.
Despite challenges, the company has shown resilience, evidenced by a 5.8% increase in third-quarter 2023 net revenues to $263 million. However, a net loss of $14 million was reported due to a $35 million legal settlement. Sotera Health’s ongoing projects include expanding its service offerings and enhancing operational efficiencies.
Headquartered in Cleveland, Ohio, the company had $2.3 billion in total debt and $245 million in cash equivalents as of September 30, 2023, reflecting a strong financial position to support its strategic initiatives. The company continues to focus on its mission of 'Safeguarding Global Health®.'
CLEVELAND, April 18, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) plans to release its financial results for the first quarter ended March 31, 2023, before market opens on May 3, 2023. Following the release, management will host a conference call at 9:00 a.m. Eastern Time to discuss operational highlights.
Participants can join the call by dialing 1-866-777-2509 from the U.S. or 1-412-317-5413 from other locations. A live webcast and materials will be available via the Company's Investor Relations section. A replay will be available later on May 3.
Sotera Health Company (Nasdaq: SHC) announced an amendment to its First Lien Credit Agreement, increasing its revolving loan commitments by $76.3 million. This boosts the total commitments under the Revolving Credit Facility from $347.5 million to $423.8 million and enhances lender commitments for letters of credit from about $196 million to $361 million. The amendment replaces the LIBOR interest rate option with Term SOFR or Daily SOFR rates. No balance is currently outstanding under this facility, and the company does not anticipate needing to borrow in the near term, maintaining a maturity date of June 13, 2026.
Sotera Health Company (SHC) reported a 4.3% increase in Q4 2022 net revenues to $252 million, despite a net loss of $320 million, significantly influenced by a $408 million legal reserve. Adjusted EBITDA rose 4% to $130 million, with Adjusted EPS improving to $0.25. For FY 2022, net revenues grew 7.8% to $1,004 million, while net loss was $234 million. The outlook for FY 2023 includes net revenue growth of 5% to 9%, with Adjusted EPS expected to decline by 10% to 19% due to rising interest expenses. The company closed a $500 million Term Loan B to address the EO settlement and enhance liquidity.
Sotera Health Company (Nasdaq: SHC) announced the successful closure of a $500 million senior secured Term Loan B facility, aimed at funding a $408 million ethylene oxide litigation settlement and enhancing liquidity. This loan, which exceeded the initially planned $425 million, will help pay down existing borrowings and address general corporate needs. The interest rates vary, and there is a mandatory annual paydown of $5 million. The company’s CEO highlighted strong market reception, emphasizing the solid profile of Sotera Health's business.
Sotera Health Company (Nasdaq: SHC) has announced the release date for its financial results for the fourth quarter and full year ending December 31, 2022. The results will be published on February 28, 2023, before the market opens. A conference call discussing the financial results will take place at 9:00 a.m. ET on the same day. Investors can participate by dialing the provided numbers or accessing the webcast via Sotera's Investor Relations website. Sotera Health, known for its sterilization solutions and lab services, operates through Sterigenics, Nordion, and Nelson Labs, focusing on its mission of safeguarding global health.
FAQ
What is the current stock price of Sotera Health Company (SHC)?
What is the market cap of Sotera Health Company (SHC)?
What services does Sotera Health Company offer?
What are the main segments of Sotera Health?
How did Sotera Health perform in the third quarter of 2023?
What are the key components of the gamma sterilization process provided by Nordion?
What financial condition is Sotera Health in as of September 30, 2023?
What recent achievements has Sotera Health made?
Where is Sotera Health headquartered?
What is the company’s mission?
What are Sotera Health’s advisory services focused on?
What recent financial results did Sotera Health announce?
